Sanofi

News

About Genzyme Company Leadership Business Units News

Press Contacts Subscribe to News

Recognition and Awards Working With Genzyme Global Reach Download Genzyme Materials

September 12, 2012 09:00 PM Eastern Time

FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis

AUBAGIO (R) 14mg

AUBAGIO (R) 14mg

Opens in new window

Download

Full Size JPEG, 2200x1700, 77.9 KB
Small JPEG, 480x371, 10.4 KB
Preview JPEG, 144x111, 4.5 KB
Thumbnail JPEG, 72x56, 3.9 KB

Smart Multimedia Gallery

AUBAGIO (R) 14mg

AUBAGIO (R) 14mg

About MS Fact Sheet

About MS Fact Sheet

View and Share Graphic

http://www.businesswire.com/multimedia/genzyme/20120912007076/en/2726990/FDA-Approves-Genzyme%E2%80%99s-AUBAGIO%C2%AE-teriflunomide-a-Once-Daily-Oral-Treatment-for-Relapsing-Multiple-Sclerosis

View and Share Logo

Download Small

View and Share Graphic

Share

Email

All News | News with Multimedia > Press Release: FDA Approves Genzyme’s AUBAGIO® (teriflunomide)...

Latest Press Releases

Keep up to date by reading the latest press releases for Genzyme.

Interactive Timeline

Explore Genzymes history, year-by-year, including key milestones, photographs, and video clips.

Launch the timeline

Targeting Unmet Needs

View our specialized portfolio of therapies, which provide personalized treatment for patients with rare diseases.

See our products list

Jobs at Genzyme

Learn about job opportunities around the world for those who are motivated by the prospect of changing patients lives for the better.

Search jobs now

genzyme a sanofi company

© 2012 Genzyme Corporation, a Sanofi company. All rights reserved.

Contact Us | Terms of Use | Privacy Policy | Site Map

infoBox